HIV protease inhibitors

US5834467A · kind A · utility

Assignee

• Agouron Pharmaceuticals, Inc. · US

Inventors

• Vincent Jacob Kalish · Annapolis, US
• Bruce A. Dressman · Indianapolis, US
• James E. Fritz · Greenwood, US
• Marlys Hammond · Blue Bell, US
• William J. Hornback · Indianapolis, US
• Stephen W. Kaldor · Indianapolis, US
• John E. Munroe · Indianapolis, US
• Siegfried H. Reich · San Diego, US
• John Howard Tatlock · San Diego, US
• Timothy Alan Shepherd · Indianapolis, US
• Michael John RODRIQUEZ · Indianapolis, US

Key dates

• Filing date: Jun 7, 1995
• Grant date: Nov 10, 1998
• Expiry date: Jun 7, 2015

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07F9/62
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.